How We WorkOrder NowSupport Privacy

Biotech Stocks in the News – ARIA, ARNA, GILD, DNDN

on 25/01/2013

Houston, TX – January 25, 2013 — (Net PR News) – AnotherWinningTrade.com, the leader for breaking information and up-to-date market activities on Wall Street, locates high-growth equity opportunities. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.

Today’s focus is on: ARIA, ARNA, GILD, DNDN

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) offered its common stock in an underwritten public offering of 15,307,000 shares, priced at $19.60 per share. On about January 29, 2013, the offering is expected to be close.

Ariad Pharmaceuticals, Inc. percentage change decreased -2.37%, to close at $19.38 with the total traded volume of 11.99 million shares, as compared to average volume of 3.45 million shares.

Get A Free Report And Detailed Analysis On ARIA CLICK HERE To Read

ARIA’s total market capitalization is $3.23 billion, along with 166.66 million shares outstanding. Its beta value stands at 1.31 points and its earning per share remained $-1.36. The Company’s lowest price during last trade was $19.25, while its highest price remained 19.54 for the day.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported a plunge of -0.12%. After opening at the price of $8.66, its closing price for the day was $8.67.

Arena Pharmaceuticals Company’s earning per share is $-0.53 while its beta value stands at 0.24 times. The Company’s current market capitalization stands at $1.88 billion, along with 217.29 million shares. ARNA’s total trading volume for the day was 8.37 million shares, versus its average volume of 11.43 million shares.

How Should Investors React To ARNA Now? Find Out In This TREND ANALYSIS REPORT

If we look at the previous 5 day’s performance of the stock, it remained decreasing with the drop of -10.25% and, in its last one month’s trade it plunged -0.57%.

Gilead Sciences, Inc. (NASDAQ:GILD)’s Executive Vice President, Research and Development and Chief Scientific Officer, Norbert Bischofberger, reported that the management of the company is pleased move TAF into Phase 3 clinical research.

Gilead Sciences, Inc. percentage change increased 2.03% to close at $78.40 with the total traded volume of 5.59 million shares, as compared to average volume of 4.56 million shares.

Is GILD A Solid Investment At These Levels? Find Out Exactly Where GILD Is Headed With This TREND ANALYSIS REPORT

GILD’s shares were trading within the range of $77.09-$78.75, while its opening price was $77.30. Its market capitalization is $59.40 billion and EPS was $3.20. If we look at its previous three months trade, it gained 14.72%, while in the last 5 day’s it remained up 1.59%.

Dendreon Corporation (NASDAQ:DNDN) reported the increase of 2.11% and closed at $6.30 with the total traded volume of 8.20 million shares. The stock’s opening price was $6.18.

52-week price range of the stock remained $3.69 – $17.04, while during last trade its minimum price was $6.18 and it gained its highest price of $6.57.

The company has a total of 154.32 million outstanding shares and its total market capitalization is $972.20 million. The Company’s last 5 days shows an uptrend of 2.11%.

How Should Investors Trade DNDN Now? Don’t Trade DNDN Until You Read This TREND ANALYSIS REPORT

Disclaimer:

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Source: anotherwinningtrade Posted Fri, January 25, 2013 12:52 - Permalink